Cheil Bio Co

Cheil Bio Co Equity Ratio

Delisted·Feb 25, 2026

The Equity Ratio of Cheil Bio Co (052670.KQ) as of Nov 17, 2026 is 92.74 %. In the previous year, Equity Ratio was 96.22 % — a change of -3.61% (lower).

Equity Ratio

92.74 %

YoY

-3.61%

Last updated:

Equity Ratio of Cheil Bio Co is 2023 92.74 % . Equity Ratio of Cheil Bio Co was 2022 96.22 % . It decreases by -3.61% lower compared to the previous year.

The Cheil Bio Co Equity Ratio history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Ratio
Date
Equity Ratio
Jan 1, 2016
89.60 KRW
Jan 1, 2017
92.49 KRW
Jan 1, 2018
91.81 KRW
Jan 1, 2019
91.25 KRW
Jan 1, 2020
89.60 KRW
Jan 1, 2021
95.33 KRW
Jan 1, 2022
96.22 KRW
Jan 1, 2023
92.74 KRW
The Cheil Bio Co Equity Ratio history
YEAREquity RatioYoY
92.74 %-3.61%
96.22 %+0.93%
95.33 %+6.39%
89.60 %-1.81%
91.25 %-0.60%
91.81 %-0.73%
92.49 %+3.22%
89.60 %+5.70%
84.78 %+17.02%
72.44 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cheil Bio Co Stock analysis

What does Cheil Bio Co do? Cheil Bio Co., Ltd. generates revenue through the production and sale of veterinary products for pigs, cattle, chickens, cows, and aquatic animals. The company offers antibiotics, antimicrobials, lactobacillus, enzyme preparations, parasiticides, antiseptics, organic trace minerals, vaccines, and diagnostic kits including ELISA test kits, virus test kits, and DNA kits. These products are primarily sold to the domestic market, targeting livestock farmers and veterinary clinics. The firm also provides feed additives as part of its product portfolio. The company's product range includes specialized solutions for cattle, pigs, chickens, pets, and other animals, with a focus on health management and disease prevention. Veterinary clinics and livestock farms form the core customer segments, purchasing antibiotics, vaccines, and diagnostic tools to maintain animal health. The domestic market remains the primary sales channel, with no mention of international distribution. Cheil Bio's offerings are designed to address common health challenges in livestock, such as infections and parasitic infestations, through both preventive and therapeutic products. The inclusion of diagnostic kits like ELISA and DNA tests supports advanced veterinary care, enhancing the company's value proposition for professional animal health providers. Cheil Bio Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cheil Bio Co stock

Equity Ratio of Cheil Bio Co is 92.74 % in 2023.

Equity Ratio of Cheil Bio Co changed from 96.22 % to 92.74 %, representing a -3.61% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Equity Ratio Cheil Bio Co since 2006 – with annual values, charts, and detailed analysis.

The equity ratio measures the proportion of total assets financed by shareholders' equity. Higher ratios indicate stronger financial independence and lower leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Equity Ratio's Cheil Bio Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Cheil Bio Co

All Key Metrics — Cheil Bio Co